|
1
|
Cha S: Perfusion MR imaging of brain
tumors. Top Magn Reson Imaging. 15:279–289. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altieri R, Agnoletti A, Quattrucci F,
Garbossa D, Calamo Specchia FM, Bozzaro M, Fornaro R, Mencarani C,
Lanotte M, Spaziante R and Ducati A: Molecular biology of gliomas:
Present and future challenges. Transl Med UniSa. 10:29–37.
2014.PubMed/NCBI
|
|
3
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15
Suppl 2:ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Porter KR, McCarthy BJ, Freels S, Kim Y
and Davis FG: Prevalence estimates for primary brain tumors in the
United States by age, gender, behavior, and histology. Neuro Oncol.
12:520–527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Labussiere M, Sanson M, Idbaih A and
Delattre JY: IDH1 gene mutations: A new paradigm in glioma
prognosis and therapy? Oncologist. 15:196–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mohrenz IV, Antonietti P, Pusch S, Capper
D, Balss J, Voigt S, Weissert S, Mukrowsky A, Frank J, Senft C, et
al: Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells
to BCNU-induced oxidative stress and cell death. Apoptosis.
18:1416–1425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balss J, Meyer J, Mueller W, Korshunov A,
Hartmann C and von Deimling A: Analysis of the IDH1 codon 132
mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ichimura K, Pearson DM, Kocialkowski S,
Bäcklund LM, Chan R, Jones DT and Collins VP: IDH1 mutations are
present in the majority of common adult gliomas but rare in primary
glioblastomas. Neuro Oncol. 11:341–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horbinski C: What do we know about IDH1/2
mutations so far, and how do we use it? Acta Neuropathol.
125:621–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song Tao Q, Lei Y, Si G, Yan Qing D, Hui
Xia H, Xue Lin Z, LanXiao W and Fei Y: IDH mutations predict longer
survival and response to temozolomide in secondary glioblastoma.
Cancer Sci. 103:269–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P
and Gu A: IDH1/IDH2 mutations define the prognosis and molecular
profiles of patients with gliomas: A meta-analysis. PLoS One.
8:e687822013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rohle D, Popovici-Muller J, Palaskas N,
Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B,
Komisopoulou E, et al: An inhibitor of mutant IDH1 delays growth
and promotes differentiation of glioma cells. Science. 340:626–630.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cohen N and Weller RO: Who classification
of tumours of the central nervous system. Wiley Online Library;
2007
|
|
19
|
Hartmann C, Meyer J, Balss J, Capper D,
Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et
al: Type and frequency of IDH1IDH2 mutations are related to
astrocytic and oligodendroglial differentiation and age: A study of
1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pollack IF, Hamilton RL, Sobol RW,
Nikiforova MN, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ,
Rosenblum MK, Holmes EJ, et al: IDH1 mutations are common in
malignant gliomas arising in adolescents: A report from the
children's oncology group. Childs Nerv Syst. 27:87–94. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Megova M, Drabek J, Koudelakova V,
Trojanec R, Kalita O and Hajduch M: Isocitrate dehydrogenase 1 and
2 mutations in gliomas. J Neurosci Res. 92:1611–1620. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hartmann C, Hentschel B, Wick W, Capper D,
Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch
T, et al: Patients with IDH1 wild type anaplastic astrocytomas
exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1
mutation status accounts for the unfavorable prognostic effect of
higher age: Implications for classification of gliomas. Acta
Neuropathol. 120:707–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lass U, Nümann A, von Eckardstein K, Kiwit
J, Stockhammer F, Horaczek JA, Veelken J, Herold-Mende C, Jeuken J,
von Deimling A and Mueller W: Clonal analysis in recurrent
astrocytic, oligoastrocytic and oligodendroglial tumors implicates
IDH1-mutation as common tumor initiating event. PLoS One.
7:e412982012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watanabe T, Nobusawa S, Kleihues P and
Ohgaki H: IDH1 mutations are early events in the development of
astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Metellus P, Coulibaly B, Colin C, de Paula
AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K,
Wang XW, et al: Absence of IDH mutation identifies a novel
radiologic and molecular subtype of WHO grade II gliomas with
dismal prognosis. Acta Neuropathol. 120:719–729. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gorlia T, Delattre JY, Brandes AA, Kros
JM, Taphoorn MJ, Kouwenhoven MC, Bernsen H, Frénay M, Tijssen CC,
Lacombe D and van den Bent MJ: New clinical, pathological and
molecular prognostic models and calculators in patients with
locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma.
A prognostic factor analysis of European organisation for research
and treatment of cancer brain tumour group study 26951. Eur J
Cancer. 49:3477–3485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li S, Chou AP, Chen W, Chen R, Deng Y,
Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, et al:
Overexpression of isocitrate dehydrogenase mutant proteins renders
glioma cells more sensitive to radiation. Neuro Oncol. 15:57–68.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dang L, White DW, Gross S, Bennett BD,
Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et
al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin G, Reitman ZJ, Spasojevic I,
Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD and Yan H:
2-hydroxyglutarate production, but not dominant negative function,
is conferred by glioma-derived NADP+-dependent
isocitrate dehydrogenase mutations. PLoS One. 6:e168122011.
View Article : Google Scholar : PubMed/NCBI
|
